Two of the world’s most promising studies to develop a vaccine for COVID-19 have said subjects in their trials have shown early signs of immunity.
The trials, run by teams at Oxford University in the UK and pharmaceutical company Moderna in the US, have both received significant government funding in their bids to develop their vaccines before the end of the year.
The Oxford vaccine, being manufactured by AstraZeneca, based in Cambridge, England, has already had millions of doses mass-produced in the event of the trials proving a success. The team behind it says it is “80 percent confident” of it being available by September.
Moderna, meanwhile, reported that all 45 volunteers in its early phase had developed immune responses after receiving its vaccine, though with more than half its subjects experiencing mild or moderate side effects including headaches, fatigue and muscle pain.